Peptide Biologix
Compound index
The atlas

Sermorelin (GHRH 1–29-NH2): Somatotropic Axis Reference Monograph

Sermorelin (GRF 1–29-NH2) is a synthetic 29-amino acid C-terminally amidated polypeptide corresponding to the N-terminal 1–29 sequence of native 44-residue human growth hormone-releasing hormone (hGHRH1–44-NH2), representing the shortest N-terminal sequence retaining full intrinsic agonist potency at the anterior pituitary GHRH receptor (GHRH-R).

Botanical plate of a young plant with its branching root system exposed
Plate 30Sermorelin
Primary Sequence (29 AA) Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Regulatory & Compounding Status (Updated April 22, 2026)

Sermorelin is a synthetic GHRH(1–29) analogue. This monograph is for laboratory and educational reference. See CJC-1295. See Ipamorelin.

1. Introduction and Overview

Human growth hormone-releasing hormone (hGHRH) is a 44-amino acid hypothalamic neurohormone first isolated in 1982 from human pancreatic islet tumors causing acromegaly (Guillemin et al., 1982; Thorner et al., 1982). Systematic C-terminal truncation studies rapidly established that residues 30–44 of native hGHRH1–44-NH2 are dispensable for receptor recognition and signal transduction: the N-terminal 29-residue amidated fragment, hGHRH(1–29)-NH2 (sermorelin), retains the full intrinsic biological activity and nanomolar receptor affinity of the native 44-mer hormone while significantly simplifying solid-phase synthesis.

In endocrine physiology and clinical research, sermorelin serves as the canonical unmodified reference standard for Class II GHRH analogues. Unlike exogenous recombinant human growth hormone (rhGH), which produces a single supraphysiological square-wave elevation of circulating GH and suppresses endogenous pituitary somatotroph activity via negative feedback, sermorelin acts upstream at the pituitary GHRH receptor. Consequently, sermorelin-stimulated GH secretion remains subject to negative feedback by circulating insulin-like growth factor-1 (IGF-1) and episodic gating by hypothalamic somatostatin (SRIF), preserving the physiological pulsatility of the somatotropic axis.

2. Molecular Characterization and Structure-Activity Relationships

2.1 Primary Structure and Physicochemical Specifications

Sermorelin is a linear 29-amino acid polypeptide with the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 (YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2). The C-terminal arginine carries a carboxamide group (-NH2), which shields against carboxypeptidase degradation and enhances receptor affinity relative to the free carboxylic acid form.

Table 1: Molecular and Physicochemical Specifications of Sermorelin
Property Value / Specification
Compound Name & Synonyms Sermorelin, GHRH(1–29)-NH2, GRF 1–29, Sermorelin acetate, Geref
CAS Registry Number 86168-78-7
Molecular Formula C149H246N44O42S
Molecular Weight 3357.93 g/mol (free base) / 3367.96 g/mol (acetate salt) (3357.92 g/mol in index/sidebar)
Three-Letter Sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Isoelectric Point (pI) ~10.5 (6 basic residues: 3 Arg, 2 Lys, N-terminal α-NH3+; 2 acidic residues: 2 Asp)
UV Extinction Coefficient (ε280) 2,980 M−1cm−1 (attributable to Tyr1 and Tyr10)
Partition Coefficient (LogP) −7.8 (highly hydrophilic in aqueous solution; >5 mg/mL solubility in water/PBS)
pH Stability Window pH 4.0–8.0 (optimal stability at pH 5.0–6.5)

2.2 Functional Domains and Structural Comparison Across Class II Analogues

Circular dichroism (CD) and 2D-NMR studies demonstrate that while sermorelin is predominantly disordered in dilute water, in membrane-mimetic environments (trifluoroethanol or phospholipid micelles) it adopts a well-defined amphipathic α-helix spanning residues 6–27 (Mayo et al., 1995). This amphipathic helix docks into the extracellular domain (ECD) of the Class B GHRH receptor, positioning the N-terminal tetrapeptide pharmacophore (Tyr1-Ala2-Asp3-Ala4) into the seven-transmembrane orthosteric pocket to trigger receptor activation.

However, because sermorelin retains the native Tyr1-Ala2 N-terminus of endogenous hGHRH, it is rapidly cleaved between Ala2 and Asp3 by circulating dipeptidyl peptidase-IV (DPP-IV, CD26), generating the inactive fragment GHRH(3–29)-NH2 and restricting sermorelin's human plasma elimination half-life to 10–20 minutes. Comparing sermorelin to second-generation Class II analogues illustrates how medicinal chemists overcame this proteolytic vulnerability:

  • CJC-1295 (Mod GRF 1–29): Incorporates four amino acid substitutions into the sermorelin 1–29 scaffold — D-Ala2 (blocking DPP-IV cleavage), Gln8 (preventing Asn8 deamidation), Ala15 (enhancing amphipathic helicity), and Leu27 (preventing Met27 sulfoxide oxidation) — extending plasma half-life to ~30 minutes (or 6–8 days when coupled to a C-terminal maleimidopropionyl-Lys30 DAC albumin-binding linker).
  • Tesamorelin: Retains the full 44-amino acid hGHRH sequence capped at the N-terminus with a trans-3-hexenoyl moiety, conferring DPP-IV resistance while preserving physiological receptor kinetics.
  • Ipamorelin & Hexarelin: Act via the orthogonal ghrelin/growth hormone secretagogue receptor (GHS-R1a / Gq–PLCβ–IP3–Ca2+ pathway) and synergize supra-additively with sermorelin when co-administered in endocrine studies (Bowers et al., 1994).

3. Mechanism of Action and Somatotroph Signaling

3.1 GHRH Receptor (GHRH-R) Activation Cascade

Sermorelin binds with high affinity (Kd 1–5 nM) to the GHRH receptor (GHRH-R), a Class B secretin-family seven-transmembrane GPCR expressed selectively on anterior pituitary somatotrophs (Mayo et al., 1995; Lanning & Carter-Su, 2006). Agonist binding triggers a well-defined intracellular signaling cascade:

  1. Gs–Adenylyl Cyclase–cAMP Pathway: Activated Gαs stimulates membrane adenylyl cyclase, increasing intracellular cAMP within 5–10 minutes and activating protein kinase A (PKA).
  2. Voltage-Gated Ca2+ Influx & Exocytosis: PKA phosphorylates L-type voltage-gated Ca2+ channels and depolarizes the somatotroph plasma membrane via Na+ conductance, driving rapid extracellular Ca2+ influx and immediate exocytosis of pre-packaged GH secretory granules (peak plasma GH at 30–60 minutes).
  3. CREB & Pit-1 Transcriptional Upregulation: PKA translocates to the nucleus and phosphorylates cAMP response element-binding protein (CREB) at Ser133, which cooperates with the pituitary-specific transcription factor Pit-1 (POU1F1) to upregulate transcription of the GH1 (growth hormone) and GHRHR genes, replenishing somatotroph GH stores during pulsatile intervals.

3.2 Somatostatin Gating and Hepatic IGF-1 Feedback

Pituitary GH release is governed by the dual push-pull interaction of stimulatory GHRH and inhibitory hypothalamic somatostatin (SRIF, acting via Gi-coupled SSTR2/SSTR5 receptors to hyperpolarize somatotrophs and inhibit adenylyl cyclase). Consequently, sermorelin elicits its largest GH secretory pulse when administered during windows of low hypothalamic somatostatin tone — most notably prior to slow-wave (stage N3) nocturnal sleep. Secreted GH subsequently binds hepatic GH receptors to activate JAK2–STAT5b signaling, elevating circulating insulin-like growth factor-1 (IGF-1) 12–24 hours post-pulse (Lanning & Carter-Su, 2006).

4. Preclinical and Clinical Research Evidence

4.1 Preclinical Cellular and Animal Studies

In dispersed rat anterior pituitary cell cultures, sermorelin stimulates GH release with an EC50 of 0.1–1.0 nM and maximal efficacy identical to full-length hGHRH(1–44)-NH2. In aged rodent models of neuroendocrine senescence, chronic sermorelin administration partially restores pituitary GH mRNA content, increases GH pulse amplitude, elevates serum IGF-1, and increases skeletal muscle protein synthesis (Corpas et al., 1993).

Table 2: Summary of Foundational Preclinical and Human Clinical Studies of Sermorelin Literature summary of published study doses, routes, and schedules.
Study / Citation Experimental Model / Population Regimen Evaluated Principal Findings
Guillemin et al., 1982; Thorner et al., 1982 Isolation & SAR of human pancreatic GHRH In vitro somatotroph bioassay & human acromegaly Characterized hGHRH(1–44)-NH2 and demonstrated that the N-terminal 1–29 fragment retains 100% intrinsic GH-releasing potency
Kelijman & Frohman, 1988 Obese vs. non-obese human subjects Acute IV GHRH(1–29) challenge before/after fasting Demonstrated that obesity and elevated free fatty acids blunt somatotroph responsiveness to GHRH, reversible with weight loss or fasting
Thorner et al., 1996 (Multicenter Pediatric Trial) Prepubertal children with growth hormone deficiency Once-daily subcutaneous GHRH(1–29) for 12 months Accelerated first-year growth velocity (mean improvements of 2–3 cm/year above baseline in idiopathic short stature; higher in hypothalamic GHD with intact somatotrophs)
Vittone et al., 1997 Healthy elderly men Single nightly subcutaneous injections of GHRH(1–29) Increased nocturnal GH secretion, elevated serum IGF-1 concentrations, and produced favorable changes in body composition (increased lean mass, reduced fat mass)
Corpas et al., 1992 / 1993 Healthy men aged 50–70 years Nightly subcutaneous GHRH(1–29) over 16 weeks Increased GH pulse amplitude, elevated mean 24-hour GH and IGF-1 levels within age-adjusted normal ranges, and modest body composition improvements

4.2 Diagnostic Pituitary Reserve Testing and Pediatric / Adult Studies

As a diagnostic agent (Geref Diagnostic), an intravenous bolus of 1.0 μg/kg sermorelin rapidly distinguishes hypothalamic GHRH deficiency (where pituitary somatotrophs remain intact and mount a brisk GH peak >10 ng/mL within 15–45 minutes) from primary pituitary insufficiency (where somatotroph destruction yields a blunted GH peak <3–5 ng/mL, Bowers et al., 1990). In pediatric growth disorder trials (Thorner et al., 1996), once-daily subcutaneous sermorelin accelerated first-year linear growth velocity in children with intact pituitary somatotrophs, though the magnitude of effect was smaller than with recombinant GH therapy and ineffective in severe primary pituitary damage.

In studies of adult GH deficiency and age-associated somatopause (Corpas et al., 1992, 1993; Vittone et al., 1997), nightly subcutaneous sermorelin administration increased nocturnal GH pulse amplitude, elevated serum IGF-1 concentrations, and improved body composition parameters (increased lean mass and reduced fat mass) while preserving pulsatile GH secretion patterns. By contrast, large-scale randomized trials such as Blackman et al. (2002) primarily employed recombinant human GH (with or without sex steroids) rather than sermorelin in healthy aged women and men, providing comparative data on direct GH axis manipulation and documenting shifts in lean tissue and visceral adiposity alongside higher rates of GH-associated fluid retention and insulin resistance.

5. Analytical Methods and Quality Control

Sermorelin is synthesized by Fmoc solid-phase peptide synthesis on Rink amide resin and purified by preparative C18 RP-HPLC. Because the 29-residue sequence contains a single oxidation-sensitive methionine residue (Met27), a deamidation-prone asparagine (Asn8), two glutamines (Gln16, Gln24), and two aspartyl bonds (Asp3-Ala4 and Asp25-Ile26), stability-indicating RP-HPLC coupled with orthogonal mass spectrometry and peptide mapping is required for Certificate of Analysis verification.

5.1 ESI-MS vs. MALDI-TOF Mass Spectrometric Characterization

Electrospray ionization mass spectrometry (ESI-MS) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) serve complementary roles in sermorelin characterization. ESI-MS generates multiply charged molecular ions (typically charge states +3 to +7 depending on ionization conditions); deconvolution of the multiply charged envelope yields the molecular mass (3357.93 Da for free base, 3367.96 Da for acetate salt) within a typical mass accuracy of ±1–2 Da on quadrupole instruments or ±0.01 Da on high-resolution analyzers. MALDI-TOF MS using α-cyano-4-hydroxycinnamic acid (CHCA) or sinapinic acid matrix generates predominantly singly charged [M+H]+ ions, offering rapid analysis times and tolerance for complex sample matrices, though with lower mass accuracy than high-resolution ESI-MS.

5.2 Tryptic Peptide Mapping and LC-MS/MS Sequence Verification

Enzymatic digestion followed by LC-MS/MS analysis provides definitive primary sequence verification for the 29-residue chain. Because sermorelin contains five basic cleavage sites (Arg11, Lys12, Arg20, Lys21, and C-terminal Arg29-NH2), trypsin digestion generates predictable diagnostic peptide fragments suitable for complete sequence coverage. Collision-induced dissociation (CID) tandem mass spectrometry produces b-ion and y-ion series across each tryptic peptide, serving as a molecular fingerprint that distinguishes authentic hGHRH(1–29)-NH2 from deletion peptides, truncated synthesis impurities, regioisomers, or site-specific deamidation/oxidation variants.

Table 3: Analytical Quality Control Specifications for Research-Grade Sermorelin
Analytical Parameter Method Acceptance Specification
Chemical Purity RP-HPLC (C18, 250 × 4.6 mm, 5 μm; 25–45% MeCN/0.1% TFA over 30 min; UV 214/280 nm) ≥95.0% (≥98.0% pharmaceutical reference grade; resolution >2.0 from nearest impurity)
Molecular Mass Identity ESI-MS or MALDI-TOF MS 3357.93 Da (free base) / 3367.96 Da (acetate salt)
Sequence Fingerprint Tryptic Digestion + LC-MS/MS (b/y fragment ion mapping) Full 1–29 sequence coverage; confirms C-terminal Arg29-NH2 amidation
Forced-Degradation / Stability Profile Stability-Indicating RP-HPLC / LC-MS Resolves Met27-sulfoxide/sulfone, Asn8/Gln16/Gln24 deamidation, Arg29-OH amide hydrolysis, and Asp-X cleavage
UV Spectrophotometric & AAA Content Absorbance at 276–278 nm (ε280 = 2,980 M−1cm−1) & 6 N HCl AAA (OPA/AQC) Amino acid ratios within ±5–10% of theoretical; water content ≤10% by Karl Fischer
Bacterial Endotoxins LAL Assay ≤5 EU/mg

6. Storage and Laboratory Stability

Lyophilized sermorelin acetate should be stored desiccated in sealed amber glass vials at −20°C (stable 24–36 months) or 2–8°C (stable 12–18 months). In aqueous laboratory buffers, solutions must be maintained at 2–8°C and protected from light and atmospheric oxygen to minimize Met27 sulfoxidation, Asn8/Gln16/Gln24 deamidation, and Asp-X peptide bond hydrolysis.

7. Safety Profile, Adverse Events, and Contraindications

Across diagnostic and chronic clinical trials, sermorelin demonstrated a favorable safety profile attributable to intact IGF-1 and somatostatin feedback regulation:

  • Local & Acute Vasomotor Reactions: Transient injection-site erythema, swelling, or discomfort (10–30%); transient facial flushing or warmth within 15–30 minutes of administration (5–15%); headache, dysgeusia (altered taste), or mild nausea (3–8%).
  • Endocrine & Pharmacological Interactions: Concomitant glucocorticoids, untreated hypothyroidism, somatostatin analogues, obesity, hyperglycemia, and elevated plasma free fatty acids blunt the pituitary GH response to sermorelin. Active malignancy and severe primary pituitary pathology are standard exclusion criteria in somatotropic axis studies. Detailed tissue-repair comparisons with BPC-157 and TB-500 involve distinct non-somatotropic pathways.

8. Primary Literature References

  1. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220.
  2. Thorner MO, Perryman RL, Cronin MJ, et al. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest. 1982;70(5):965-977. doi:10.1172/JCI110706.
  3. Bowers CY, Veeraragavan K, Sethumadhavan K. Atypical growth hormone releasing peptides. In: Bercu BB, Walker RF, eds. Growth Hormone II: Basic and Clinical Aspects. Springer-Verlag; 1994:203-222.
  4. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39. doi:10.1210/edrv-14-1-20.
  5. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. doi:10.1016/s0026-0495(97)90173-8.
  6. Blackman MR, Sorkin JD, Münzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288(18):2282-2292. doi:10.1001/jama.288.18.2282.
  7. Mayo KE, Godfrey PA, Suhr ST, Kulik DJ, Rahal JO. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res. 1995;50:35-73. doi:10.1016/b978-0-12-571150-0.50007-6.
  8. Lanning NJ, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord. 2006;7(4):225-235. doi:10.1007/s11154-007-9025-5.
  9. Thorner MO, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-1196. doi:10.1210/jcem.81.3.8772598.
  10. Kelijman M, Frohman LA. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects. J Clin Endocrinol Metab. 1988;66(3):489-494. doi:10.1210/jcem-66-3-489.